BeOne Medicines (ONC) Gross Margin (2017 - 2026)

BeOne Medicines (ONC) has 10 years of Gross Margin data on file, last reported at 88.95% in Q1 2026.

• On a quarterly basis, Gross Margin rose 372.0% year-over-year to 88.95% in Q1 2026; TTM through Mar 2026 was 88.31%, a 350.0% increase from a year earlier, with the FY2025 full-year figure at 87.49%, up 308.0% from the prior year.
• Gross Margin for Q1 2026 stood at 88.95%, down from 90.49% in the prior quarter.
• Over the last five years, Gross Margin for ONC reached as high as 90.49% in Q4 2025 and fell as low as 78.72% in Q1 2022.
• Historically, Gross Margin has averaged 84.17% across 5 years, with a median of 83.87% in 2023.
• Across the five-year window, Gross Margin plunged 1588 bps in 2022 and jumped 742 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 80.66% in 2022, then gained by 3 bps to 83.32% in 2023, then grew by 3 bps to 85.76% in 2024, then gained by 6 bps to 90.49% in 2025, then slipped by 2 bps to 88.95% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 88.95% in Q1 2026, 90.49% in Q4 2025, and 86.09% in Q3 2025.